NCT01746043View on ClinicalTrials.gov

A Phase II Study of Minocycline and Armodafinil for Reducing the Symptom Burden Produced by Chemoradiation Treatment for Esophageal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

January 31, 2017

Study Completion Date

January 31, 2017

Conditions
Esophageal Cancer
Interventions
DRUG

Armodafinil

150 mg by mouth once a day for 6 weeks.

OTHER

Placebo

1 capsule by mouth 2 times a day for 6 weeks.

DRUG

Minocycline

100 mg by mouth 2 times a day for 6 weeks.

BEHAVIORAL

Questionnaires

Completion of symptom questionnaires before chemoradiation and then 1 time a week during Weeks 1-10 of the study. Questionnaire take up to 5 minutes to complete.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT01746043 - A Phase II Study of Minocycline and Armodafinil for Reducing the Symptom Burden Produced by Chemoradiation Treatment for Esophageal Cancer | Biotech Hunter | Biotech Hunter